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Aim We sought to determine achievement of lipid targets according to cur-
rent European guidelines (low-density lipoprotein cholesterol [LDL-C]
≤70mg/dL) in patients with stable coronary heart disease (CHD) with or
without lipid-lowering therapy (LLT), in the French cohort of the Dyslipid-
emia International Study IICHD (DYSIS IICHD).
Methods DYSIS IICHD was a multicentre observational cross-sectional
study conducted from July 2013 to October 2014 in 27 centres in France.
Adults with stable CHD (defined as ≥1 of the following: >50% stenosis on
coronary angiography or computed tomography, prior percutaneous coronary
intervention, prior coronary bypass graft, history of ACS >3 months previ-
ously) and a fasting lipid profile done within the previous 12 months were
consecutively enrolled. Eligible patients had to be on LLT for ≥3 months or
taking no LLT.
Results A total of 436 CHD patients were enrolled. Of the 424 patients
(97.2%) on LLT, 91.5% were on statin treatment at the moment of inclusion
(mean±SD dose calculated in atorvastatin 27±23mg/day). Non-statin LLT was
used in 17.7% patients (79.2% were on a cholesterol-absorption inhibitor).
Mean±SD LDL-C was 87.4±30.5mg/dL, 28.4% achieved LDL-C<70mg/dL,
and 67.7% had an LDL-C<100mg/dL (Table).
Conclusions These observational data from contemporary clinical practice
in France indicate suboptimal lipid control, with over two-thirds of high-risk
CHD patients failing to achieve the LDL-C target despite taking LLT, and a
large difference between mean value and target LDL-C. More-intensive treat-
ment is required to optimize achievement of lipid goals in CHD.
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Background Coronary artery disease is the leading cause of cardiovascular
diseases, which remains the major cause of death for women. Prevention,
screening and diagnosis tend to be performed at late stages and less fre-
quently, and treatments are not optimal in women. The consequences of a tar-
geted screening for myocardial ischemia in women at risk have not yet been
studied.
Methods We conducted a prospective observational study with retrospec-
tive data collection based on a cohort of female patients at cardiovascular risk,
with or without symptoms, who benefited from a non-invasive diagnostic test,
offered through the care pathway “Heart, arteries and women” from the Lille
University hospital of Lille, between January 1st, 2013 and June 31st, 2014.
The objective was to determine the relevance of this screening and which fac-
tors would help in targeting women more efficiently.
Results The screening gave a positive result in for 15.7% of the
287 women included. 
Among the 30 women that benefited from a coronarography, 72% had no
obstructive coronary artery disease. The independent predictive factors of a
positive screening were a menopause since more than 5 years (OR=4.17;
p=0.001), an HDL-c ≤0.5 g/dL (OR=2.45; p=0.023) and an IMC ≥32
(OR=4.58; p=0.0001). A clinical coronary score based on these factors was
developed to target the screening (AUC 0.765). The symptoms, presents in
half of the patients, were predictive of a positive screening (p=0.010) but were
mostly atypical. 
The classical cardiovascular risk scores were inefficient at predicting a cor-
onary artery disease (AUC 0.618 to 0.681). The positive screening had
resulted into a low rate of revascularization (17%) but in a significant increase
of in the prescription of statin (p=0.002), antiplatelet agents (p<0.0001) and
beta blockers (p=0.024).
Conclusion The screening for myocardial ischemia among selected women
at risk of cardiovascular diseases allows optimizing their care in secondary
prevention. 
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Introduction Coronary artery disease is a public health problem, whose
prognosis and management depend on the development of lesions, hence the
need to determine the profile of patients most at risk of developing major
lesions, as well as items that can influence their prognosis.
Objective The aim of our study is to identify the epidemiological profile
of patients treated for acute coronary syndrome or explored for effort angina
and have a documented three-vessel coronary disease. The second objective is
to identify mortality factors.
Method This is a descriptive study that examined patients records hospital-
ized for coronary artery disease during the period from Jan 2007 to Dec 2012
and who have a three vessel coronary disease. The mean of follow up is
4 years. 
Results During the period, 365 patients were hospitalized. This is 23%
women and 77% of men (3.5 /1); the average age was 64 years for men VS
69 years for women (p<0.001). The reason for hospitalization was 44% of
STEMI, 33% NSTEMI, 23% of effort angina. Diabetic patients accounted for
49%, 66% women vs 47% of men (p=0.001). Hypertension is present in 60%
of patients. 34% of patients were smokers. Left ventricular function was
Abstract 0191 – Table: Characteristics of lipid values in patients with stable
CHD
All patients 
(n=436)
LLT 
(n=424)
No LLT 
(n=12)
Age (years) 69±12 69±12 74±12
Men 80.0 79.7 91.7
ACS >3 months previously 70.0 70.0 66.7
Diabetes type 2 27.0 27.3 16.7
Chronic kidney disease 5.0 5.2 0
Lipid variables
LDL-C (mg/dL) 87.4±30.5 86.0±29.6 135.3±24.5**
LDL <70 mg/dL 28.4 29.2 0*
Distance to target 
of <70 mg/dL (mg/dL) 31.1±24.2 29.7±23.2 65.3±24.5**
LDL <100 mg/dL 67.7 69.3 8.3**
Data are mean±SD or %. *P<0.05; **P?0.0001 (LLT vs no LLT)
